Glenmark Pharmaceuticals Limited
UTI Mutual Fund decreased its stake in Glenmark Pharmaceuticals from 1.27% to 1.15%, selling 3,19,539 shares worth ₹71.55 crore at ₹2235.50 apiece.
A global research-led pharmaceutical company, Glenmark operates across generics, specialty, and over-the-counter business segments with a presence in more than 80 countries worldwide. The company develops and manufactures pharmaceutical products serving patients across multiple therapeutic areas including oncology, dermatology, and respiratory care. Its distinctive strength lies in combining generic drug manufacturing capabilities with specialty pharmaceutical development and maintaining a robust international distribution network across developed and emerging markets.
India's oldest and most storied asset manager, founded in 1963 as the Unit Trust of India under an Act of Parliament. Now manages over Rs 3.5 lakh crore with backing from four public sector institutions: LIC, SBI, Bank of Baroda, and Punjab National Bank. CIO Vetri Subramaniam is a long-term compounder with a consistent quality tilt and clear articulation of process.